en.Wedoany.com Reported - Eupraxia Pharmaceuticals Inc. reported financial results for the second quarter of 2026 on August 11, 2026, with a net loss of $14.5 million for the quarter, compared to a net loss of $8.7 million in the same period of the prior year. The company, a clinical-stage biotechnology company whose proprietary Diffsphere™ technology is used to optimize localized, controlled drug delivery, reports all financial figures in U.S. dollars.
The increase in net loss was primarily driven by higher research and development costs and general and administrative expenses resulting from the doubling in size of Part 2 of the RESOLVE trial, partially offset by an increase in other income. As of June 30, 2026, the company held $52.4 million in cash and cash equivalents and $81.2 million in short-term investments, compared to a cash balance of $80.6 million at the end of the fourth quarter of 2025. These funds are expected to support the EP-104GI clinical trials, general and administrative expenses, working capital requirements, and other corporate purposes. The company expects its existing cash reserves to fund operations into the second half of 2028. As of June 30, 2026, the company had 65,474,223 common shares, 8,295,638 preferred shares, and 1,428,571 pre-funded warrants outstanding.
Dr. James A. Helliwell, Chief Executive Officer of the company, stated that the company is well-funded and has an experienced team to advance upcoming key milestones, including the planned release of interim data from the Phase 2b eosinophilic esophagitis (EoE) trial in the fourth quarter, which will cover key clinical and histologic endpoints; followed by the initiation of a Phase 3 trial; and plans to expand the targeted indications of EP-104GI into a broader gastroenterology product portfolio by 2027. He noted that the unmet need among EoE patients was evident at this year's DDW conference, and combined with the clinical improvements, fibrosis reversal, and endoscopic remission demonstrated in additional data, the company believes EP-104GI has the potential to become an effective and durable treatment option.
On April 21, 2026, the company reported nine-month tissue health and symptom data from the highest-dose cohort of its ongoing Phase 1b/2a RESOLVE trial in EoE. Cohort 9 (n=3) demonstrated greater tissue health response at Week 36 than all other dose cohorts; 66% of patients in this cohort (2 of 3) maintained clinical remission of symptoms at Week 36, with this level of remission achieved as early as Week 8 and sustained through Week 36.
On May 5, 2026, the company presented EREFS data from the RESOLVE trial at DDW. EREFS is a standardized visual scoring system used by gastroenterologists during endoscopy to assess the severity of esophageal inflammation and fibrosis in EoE patients, and the data showed an association between EP-104GI injection counts and overall improvement in EREFS results. On May 6, the company presented EoEHSS subscore data from the trial. EoEHSS is a standardized method for monitoring esophageal tissue damage in EoE patients, with subscores specifically assessing tissue inflammation and tissue remodeling (fibrosis indicators). The highest-dose cohort subscore data reported at this time were presented for the first time at DDW, and overall showed improvements in both inflammation and fibrosis following EP-104GI treatment.
Regarding personnel appointments, on May 4, 2026, Dr. Jeymi Tambiah joined the company as Chief Medical Officer. On July 7, three industry leaders in drug development and commercialization—Robert Bazemore, Amy Pott, and Helen Thackray—joined the Board of Directors. On July 13, Dr. Jeff Millard was appointed Executive Vice President, Head of Technical Operations; Dr. Alex Therien, who joined the company in November 2025, was appointed Executive Vice President, Head of Research and Development. The company's operations were simultaneously transitioned from Victoria to a dual-center organization based in Vancouver and Seattle, and Amanda Malone, former Chief Scientific and Operations Officer, stepped down from her role.
Eupraxia is focused on developing locally delivered, extended-release products to address therapeutic areas with highly unmet medical needs. Diffsphere™ is its proprietary polymer-based microsphere technology designed to facilitate targeted delivery of existing and new drugs to extend duration of action and deliver drugs ultra-locally to the tissue where physicians need to treat. The company believes that, compared to the drug concentration peaks and troughs seen with conventional administration methods, this technology has the potential to reduce adverse events through precise targeting and smooth delivery of the active ingredient. The technology platform has the potential to enhance and reformulate existing FDA-approved drugs to improve their safety, tolerability, efficacy, and duration of action, with potential applications potentially extending to oncology, infectious diseases, and other major disease areas beyond pain and inflammatory gastroenterology. EP-104GI is currently being studied for the treatment of EoE through the RESOLVE trial, using local administration via injection directly into the esophageal wall. Additional information is available on the company's website at www.eupraxiapharma.com.
